US Patent

US9901539 — Transmucosal drug delivery devices for use in chronic pain relief

Method of Use · Assigned to Biodelivery Sciences International Inc · Expires 2032-12-21 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating chronic pain using low doses of buprenorphine administered via a transmucosal drug delivery device.

USPTO Abstract

Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Drugs covered by this patent

Subutex (Buprenorphine Hydrochloride) · Indivior

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1556`	—	Subutex
`U-1556`	—	Subutex
`U-1556`	—	Subutex
`U-1556`	—	Subutex
`U-1556`	—	Subutex
`U-1556`	—	Subutex
`U-1556`	—	Subutex

Patent Metadata

Patent number: US9901539
Jurisdiction: US
Classification: Method of Use
Expires: 2032-12-21
Drug substance claim: No
Drug product claim: No
Assignee: Biodelivery Sciences International Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.